Circadian rhythm regulation

Circadian rhythm regulation" is not a single molecule or receptor, but rather refers to a complex biological process governed by an interlocking network of core clock genes and proteins. In mammals, this system is centered in the suprachiasmatic nucleus (SCN) in the hypothalamus, which acts as the master pacemaker. The molecular machinery involves transcription factors such as CLOCK and BMAL1 that form heterodimers to activate expression of Period (PER1, PER2, PER3) and Cryptochrome (CRY1, CRY2) genes. These gene products then inhibit their own transcription through negative feedback loops, creating oscillations with an approximately 24-hour period. Additional regulators include nuclear receptors like Rev-erbα/β (NR1D1/NR1D2) and RORα/β/γ that modulate BMAL1 expression[1][2][3]. This tightly regulated network synchronizes numerous physiological functions—including sleep-wake cycles, hormone secretion, metabolism—with environmental cues such as light. "Circadian rhythm regulation" is not itself a therapeutic target or molecule; it describes a broad physiological process controlled by multiple interacting proteins and feedback loops. For structured data extraction or drug discovery purposes, you should refer instead to specific core components—such as "Brain and muscle ARNT-like 1" (BMAL1), "Circadian locomotor output cycles kaput" (CLOCK), "Period circadian protein 2" (PER2), etc.—rather than this general term[3][4]. Drugs typically target specific components such as melatonin receptors, not the overall "circadian rhythm regulation" system. Mechanisms of action are described for drugs acting on individual circadian regulators, e.g., melatonin receptor agonists. Biomarkers exist for specific circadian genes/proteins but not for the overall regulatory process. Safety concerns relate to targeting individual components rather than the entire regulatory system.

Other names

Circadian clockBiological clockCircadian molecular machineryMolecular clockwork